ArticleActa pharmaceutica Sinica. B2026

Potential oncogenic risks of Keap1-targeting PROTACs: Caution warranted in drug design.

Zhe Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.